跳转至内容
Merck
CN
  • Loss of SOCS3 in myeloid cells prolongs survival in a syngeneic model of glioma.

Loss of SOCS3 in myeloid cells prolongs survival in a syngeneic model of glioma.

Oncotarget (2016-03-12)
Braden C McFarland, Margaret P Marks, Amber L Rowse, Samuel C Fehling, Magda Gerigk, Hongwei Qin, Etty N Benveniste
摘要

In glioma, microglia and macrophages are the largest population of tumor-infiltrating cells, referred to as glioma associated macrophages (GAMs). Herein, we sought to determine the role of Suppressor of Cytokine Signaling 3 (SOCS3), a negative regulator of Signal Transducer and Activator of Transcription 3 (STAT3), in GAM functionality in glioma. We utilized a conditional model in which SOCS3 deletion is restricted to the myeloid cell population. We found that SOCS3-deficient bone marrow-derived macrophages display enhanced and prolonged expression of pro-inflammatory M1 cytokines when exposed to glioma tumor cell conditioned medium in vitro. Moreover, we found that deletion of SOCS3 in the myeloid cell population delays intracranial tumor growth and increases survival of mice bearing orthotopic glioma tumors in vivo. Although intracranial tumors from mice with SOCS3-deficient myeloid cells appear histologically similar to control mice, we observed that loss of SOCS3 in myeloid cells results in decreased M2 polarized macrophage infiltration in the tumors. Furthermore, loss of SOCS3 in myeloid cells results in increased CD8+ T-cell and decreased regulatory T-cell infiltration in the tumors. These findings demonstrate a beneficial effect of M1 polarized macrophages on suppressing glioma tumor growth, and highlight the importance of immune cells in the tumor microenvironment.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
抗血管性假血友病因子抗体, Chemicon®, from rabbit